IJPR  articles are Indexed in SCOPUS (2010 - 2021)Click Here     *Five Years Citation in Google scholar (2016 - 2020) is. 1451*        Now IJPR is Q2 in SJR Ranking     Scopus Coverage of IJPR (2010-2021 Issue 1)            

logo

INTERNATIONAL JOURNAL OF PHARMACEUTICAL RESEARCH

A Step Towards Excellence

IJPR included in UGC-Approved List of Journals - Ref. No. is SL. No. 4812 & J. No. 63703

Published by : Advanced Scientific Research
ISSN
0975-2366
Current Issue
Article In Press
No Data found.
ADOBE READER

(Require Adobe Acrobat Reader to open, If you don't have Adobe Acrobat Reader)

Index Page 1
Click here to Download
IJPR 9[3] July - September 2017 Special Issue

July - September 9[3] 2017

Click to download
 

Article Detail

Label
Label
Discovery of COVID-19 and VOC 20 2012/01 life cycles and the proposed drugs to treat patients

Author: TAMER I.ABDEL-WAHAB, SHERIF I.ABDEL-WAHAB, EMAN I.ABDEL-WAHAB, MANAL M.ADEL
Abstract: The objective of this study was to detect the role of the proposed anti-virus drugs EGYPTONA and EGYPTOVA in controlling the COVID-19 and VOC 20 2012/01 life cycles in human blood. Some derivatives of neuraminic acid that liked to glycoproteins on the surface of RBCs are the common factor for facilitating infection with COVID-19 in all its strains, but the original strain is dependent on the presence of furin protease as a receptor for the virus more than the other receptors. The patient that has flu symptoms should be checked the level of iron in his blood, such as “serum ferritin” and “serum transferrin to choose the proposed anti-virus drug EGYPTONA or EGYPTOVA. When the level of iron in the blood is higher than the normal level in patients with COVID-19, the proposed anti-virus drug EGYPTONA would be treating most of the disease symptoms. Likewise, the proposed anti-virus drug EGYPTOVA would be suitable in presence of normal iron levels or anemia to treat patients with VOC 20 2012/01.
Keyword: COVID-19 life cycle, VOC 20 2012/01 life cycle, Clinical Reasoning, EGYPTONA drug, EGYPTOVA drug.
DOI: https://doi.org/10.31838/ijpr/2021.13.02.053
Download: Request For Article
 




ONLINE SUBMISSION
USER LOGIN


Username
Password
Login | Register
News & Events
SCImago Journal & Country Rank

Terms and Conditions
Disclaimer
Refund Policy
Instrucations for Subscribers
Privacy Policy

Copyrights Form

0.12
2018CiteScore
 
8th percentile
Powered by  Scopus
Google Scholar

hit counters free